These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23780998)

  • 21. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of mutations in the RET proto-oncogene in patients with medullary thyroid tumor].
    Amosenko FA; Brzhezovskiĭ VZh; Liubchenko LN; Shabanov MA; Kozlova VM; Vanushko VE; Kazubskaia TP; Gar'kavtseva RF; Kalinin VN
    Genetika; 2003 Jun; 39(6):847-54. PubMed ID: 12884527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTOR activation in medullary thyroid carcinoma with RAS mutation.
    Lyra J; Vinagre J; Batista R; Pinto V; Prazeres H; Rodrigues F; Eloy C; Sobrinho-Simões M; Soares P
    Eur J Endocrinol; 2014 Nov; 171(5):633-40. PubMed ID: 25163725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma.
    Ciampi R; Romei C; Cosci B; Vivaldi A; Bottici V; Renzini G; Ugolini C; Tacito A; Basolo F; Pinchera A; Elisei R
    Mol Cell Endocrinol; 2012 Jan; 348(1):176-82. PubMed ID: 21867742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia.
    Saggiorato E; Rapa I; Garino F; Bussolati G; Orlandi F; Papotti M; Volante M
    J Mol Diagn; 2007 Apr; 9(2):214-9. PubMed ID: 17384213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.
    Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
    Menon MM; Simha MR
    Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.
    Jindrichová S; Vcelák J; Vlcek P; Neradilová M; Nemec J; Bendlová B
    J Endocrinol; 2004 Nov; 183(2):257-65. PubMed ID: 15531714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
    Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
    Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening.
    Kaldrymides P; Mytakidis N; Anagnostopoulos T; Vassiliou M; Tertipi A; Zahariou M; Rampias T; Koutsodontis G; Konstantopoulou I; Ladopoulou A; Bei T; Yannoukakos D
    Clin Endocrinol (Oxf); 2006 May; 64(5):561-6. PubMed ID: 16649977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome.
    Frisk T; Zedenius J; Lundberg J; Wallin G; Kytölä S; Larsson C
    Int J Oncol; 2001 Jun; 18(6):1219-25. PubMed ID: 11351254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.
    Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP
    Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
    Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
    Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
    Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
    Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
    [No Abstract]   [Full Text] [Related]  

  • 35. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
    Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
    Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer.
    Romei C; Ugolini C; Cosci B; Torregrossa L; Vivaldi A; Ciampi R; Tacito A; Basolo F; Materazzi G; Miccoli P; Vitti P; Pinchera A; Elisei R
    Thyroid; 2012 May; 22(5):476-81. PubMed ID: 22404432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy.
    Darabi S; Adeyelu T; Elliott A; Sukari A; Hodges K; Abdulla F; Zuazo CE; Wise-Draper T; Wang T; Demeure MJ
    J Am Coll Surg; 2024 Jul; 239(1):50-60. PubMed ID: 38651727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
    Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
    PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
    J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
    Simbolo M; Mian C; Barollo S; Fassan M; Mafficini A; Neves D; Scardoni M; Pennelli G; Rugge M; Pelizzo MR; Cavedon E; Fugazzola L; Scarpa A
    Virchows Arch; 2014 Jul; 465(1):73-8. PubMed ID: 24828033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.